STING Pathway Targeted Therapies: Competitive Landscape, Clinical Trial Landscape, Literature Review, Patent & Deal Analysis, 2021
30-04-2021
STING Pathway Targeted Therapies: Competitive Landscape, Clinical Trial Landscape, Literature Review, Patent & Deal Analysis, 2021
- Report Pages : ~200
- Publication Date : 30-04-2021
- Geography : Global
- Delivery Timeline : 5 Business Days
- Report Code : CIPMA1978
- Available Format : PDF
| Single User License | $3000 | Buy |
|---|---|---|
| Site License | $4000 | Buy |
| Global License | $5000 | Buy |
CmaxInsight’s,
“STING Pathway Targeted Therapies: Competitive Landscape, Clinical Trial
Landscape, Literature Review, Patent & Deal Analysis, 2021”, the report
provides a comprehensive landscape of the pipeline drugs across this mechanism of
action. The report includes the detailed analysis of 45+ products along with 30+
active companies involved. The report includes-
Chapter 1: STING Overview
The introductory chapter provides details related to the STING pathway and its role in signaling. The chapter also lays emphasis on the role of STING in oncological disorders, autoimmune diseases and antimicrobial host defense. In addition, it also describes key variants of STING and the non-immunological functions of the pathway. This report also provides information about the challenges associated with STING targeted therapies along with the limitation of 1st and 2nd generation of STING agonist.
Chapter 2: Therapeutics Metrics
Pipeline Therapeutics Landscape Analysis: A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), the phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first-line or greater).
Developer Landscape Analysis: The chapter also features an analysis of the developer landscape including information on the year of establishment, company size, geography and most active players.
Clinical Trial Landscape Analysis: This section features an analysis on the clinical trials focused on STING, along with information on parameters, such as Recruitment Status, Study Start date & Stage of development, Primary completion Date & Stage of Development, study design and clinical endpoints.
Chapter 3: Competitive Landscape
This section provides detailed information about the therapeutics targeting STING which are in various stage of development (Phase III, Phase II, Phase I, IND, Pre-clinical, and Discovery). Each product profile covers a brief overview of the therapy, its clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent, and designations details along with future milestones.
Chapter 4: Technology Landscape
A descriptive information of the various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).
Chapter 5: Deal Landscape
This chapter provides a comprehensive understanding of the various partnerships (R&D and commercialization agreements, product/technology licensing agreements, mergers and acquisitions, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals) pertaining to STING targeted therapies. The chapter highlights analysis based on year of partnerships, type of the partnership model, type of STING modulator, therapeutic area, technology platform, the most active player(s) (in terms of number of partnerships inked), and region.
Chapter 6: Funding & Financing Landscape
An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies. The chapter highlights analysis based on the number of funding instances, the amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, the most active player(s) (in terms of number of funding instances), and geographical region.
Chapter 7: Literature Review
A detailed publication analysis of peer-reviewed, scientific articles published during the period 2019 to Q2 2021, highlighting the research focus within the industry. An analysis will be performed based on various relevant parameters, such as study type, year of publication, study objective, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players.
Chapter 8: Patent Analysis
An in-depth analysis of the various patents that have been filed/granted related to STING targeted therapies. It includes information on key parameters, such as patent type, publication year, issuing authority, emerging focus areas and leading industry / academic players.
Chapter 9: Company Profiling
Detailed profiles of developers engaged in the development of therapeutics targeting STING pathway, featuring information (such as Year of Establishment, Type of Entity, Headquarter Location, Company Presence, Number of Employees, Key Members of the Executive team), along with descriptions of its financial information, recent collaborations, and recent developments. In addition, each profile includes an informed future outlook.
Chapter 10: Key Insight
This section summarizes the entire report. It offers a list of key takeaways on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the STING targeted therapies.
Chapter 11: Appendix This section provides tabulated data and numbers for all the figures included in the report.
Chapter 1: STING Overview
The introductory chapter provides details related to the STING pathway and its role in signaling. The chapter also lays emphasis on the role of STING in oncological disorders, autoimmune diseases and antimicrobial host defense. In addition, it also describes key variants of STING and the non-immunological functions of the pathway. This report also provides information about the challenges associated with STING targeted therapies along with the limitation of 1st and 2nd generation of STING agonist.
Chapter 2: Therapeutics Metrics
Pipeline Therapeutics Landscape Analysis: A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), the phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first-line or greater).
Developer Landscape Analysis: The chapter also features an analysis of the developer landscape including information on the year of establishment, company size, geography and most active players.
Clinical Trial Landscape Analysis: This section features an analysis on the clinical trials focused on STING, along with information on parameters, such as Recruitment Status, Study Start date & Stage of development, Primary completion Date & Stage of Development, study design and clinical endpoints.
Chapter 3: Competitive Landscape
This section provides detailed information about the therapeutics targeting STING which are in various stage of development (Phase III, Phase II, Phase I, IND, Pre-clinical, and Discovery). Each product profile covers a brief overview of the therapy, its clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent, and designations details along with future milestones.
Chapter 4: Technology Landscape
A descriptive information of the various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).
Chapter 5: Deal Landscape
This chapter provides a comprehensive understanding of the various partnerships (R&D and commercialization agreements, product/technology licensing agreements, mergers and acquisitions, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals) pertaining to STING targeted therapies. The chapter highlights analysis based on year of partnerships, type of the partnership model, type of STING modulator, therapeutic area, technology platform, the most active player(s) (in terms of number of partnerships inked), and region.
Chapter 6: Funding & Financing Landscape
An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies. The chapter highlights analysis based on the number of funding instances, the amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, the most active player(s) (in terms of number of funding instances), and geographical region.
Chapter 7: Literature Review
A detailed publication analysis of peer-reviewed, scientific articles published during the period 2019 to Q2 2021, highlighting the research focus within the industry. An analysis will be performed based on various relevant parameters, such as study type, year of publication, study objective, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players.
Chapter 8: Patent Analysis
An in-depth analysis of the various patents that have been filed/granted related to STING targeted therapies. It includes information on key parameters, such as patent type, publication year, issuing authority, emerging focus areas and leading industry / academic players.
Chapter 9: Company Profiling
Detailed profiles of developers engaged in the development of therapeutics targeting STING pathway, featuring information (such as Year of Establishment, Type of Entity, Headquarter Location, Company Presence, Number of Employees, Key Members of the Executive team), along with descriptions of its financial information, recent collaborations, and recent developments. In addition, each profile includes an informed future outlook.
Chapter 10: Key Insight
This section summarizes the entire report. It offers a list of key takeaways on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the STING targeted therapies.
Chapter 11: Appendix This section provides tabulated data and numbers for all the figures included in the report.
Table of Contents
1. Introduction1.1. Stimulator of Interferon Genes (STING) Pathway
1.2. STING Signaling
1.2.1. Relevance in Cancer
1.2.2. Relevance in Autoimmune Diseases
1.2.3. Relevance in Antimicrobial Host Defense 1.3. STING Pathway Modulators
1.3.1. STING Agonists
1.3.2. STING Antagonists
1.3.3. STING Activating Drug Delivery Systems
1.3.4. Indirect STING Activating Therapies
1.5. Non-immunological Functions of the STING Pathway
2. STING Pathway Targeting Therapies: Therapeutic Metrics
2.1. Pipeline Therapeutics Landscape Analysis
2.1.1. Analysis by Stage of Development
2.1.2. Analysis by Company & Stage of Development
2.1.3. Analysis by MOA
2.1.4. Analysis by MOA & Stage of Development
2.1.5. Analysis by MOA & Company
2.1.6. Analysis by Therapy Area
2.1.7. Analysis by Therapy Area & Stage of Development
2.1.8. Analysis by Company & Therapy Area
2.1.9. Analysis by Molecule Type
2.1.10. Analysis by Molecule Type & Stage of Development
2.1.11. Analysis by Route of Administration
2.1.12. Analysis by Route of Administration & Stage of Development
2.1.13. Analysis by Line of Treatment
2.1.14. Analysis by line of Treatment & Stage of Development
2.2. Developer Landscape Analysis
2.2.1. Analysis by Year of Establishment
2.2.2. Analysis by Company Size
2.2.3. Analysis by Geography
2.2.4. Most Active Players
2.3. Clinical Trial Landscape Analysis
2.3.1. Analysis by Trial Recruitment Status & Stage of Development
2.3.2. Analysis by Study Start date & Stage of Development
2.3.3. Analysis by Primary Completion Date & Stage of Development
3. STING Pathway Targeting Therapies: Competitive Landscape
3.1. Chapter Overview
3.1. Mid Stage Therapeutics (Phase II)
MK-1454: Merck ·
- Product Description ·
- Clinical Development Activities ·
- Key Development Highlights ·
- Upcoming Milestone
- Product Description ·
- Clinical Development Activities ·
- Key Development Highlights ·
- Upcoming Milestone
SYNB1891: Synlogic ·
- Product Description ·
- Clinical Development Activities ·
- Key Development Highlights ·
- Upcoming Milestone
- Product Description ·
- Clinical Development Activities ·
- Key Development Highlights ·
- Upcoming Milestone
ISD017: ISD Immunotech ·
- Product Description
- Clinical Development Activities
- Key Development Highlights
- Upcoming Milestone
- Product Description ·
- Clinical Development Activities ·
- Key Development Highlights ·
- Upcoming Milestone
4. STING Pathway Targeting Technologies: Technology Landscape
4.1. Chapter Overview
4.2. STING Pathway Targeting Technologies: List of Technology Developers
4.2.1. Analysis by Type of Modulator
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Year of Establishment
4.2.4. Analysis by Company Size
4.2.5. Analysis by Geography
5. STING Pathway Targeting Therapies: Deal Landscape
5.1. Chapter Overview
5.2. STING Pathway Targeting Therapeutics: Recent Partnerships
5.2.1. Deal Distribution by Year
5.2.2. Deal Distribution by Type of Deal
5.2.3. Deal Distribution by Year and Type of deal
5.2.4. Deal Distribution by Type of STING Modulator
5.2.5. Deal Distribution by Therapeutic Area
5.2.6. Deal Distribution by Therapeutic Area by Type of STING Modulator
6. STING Pathway Targeting Therapies: Funding & Finance Analysis
6.1. Chapter Overview
6.2. STING Pathway Targeting Therapeutics: Recent Funding Instances
6.2.1. Year Wise Financing & Funding Analysis 6.2.2. Analysis by Number of Funding Instances
6.2.3. Analysis by Amount Invested
6.2.4. Analysis by Type of Funding
7. STING Pathway Targeting Therapies: Literature Review
7.1. Chapter Overview
7.2. STING Pathway Targeting Therapeutics: Recent Publications
7.2.1. Analysis by Year
7.2.2. Analysis by Type of STING Modulator
7.2.3. Analysis by Target Pathway
7.2.4. Analysis by Therapeutic Area
7.2.5. Leading Players: Analysis by Number of Publications
8. STING Pathway Targeting Therapies: Literature Review
8.1. Chapter Overview
7.2. STING Pathway Targeting Therapeutics: Patent Competitive Landscape
7.2.1. Analysis by Publication Year
7.2.2. Analysis by Filing Year 7.2.3. Analysis by Leading Players
9. STING Pathway Targeting Therapies: Company Profiles
9.1. Chapter Overview
9.2. Aduro Biotech
9.2.1. Company Overview
9.2.2. Financial Information
9.3. Bristol-Myers Squibb
9.3.1. Company Overview
9.3.2. Financial Information
9.4. Eisai
9.4.1. Company Overview
9.4.2. Financial Information
10. STING Pathway Targeting Therapies: Key Insights
11. Appendix
**Note: Please send us the email at [email protected] to request sample page or any other query!! Thanks.
Please contact us at [email protected] and WhatsApp: +1 3152150300 to request sample page or any other query regarding STING Pathway Targeted Therapies report!! Thanks.